Bryan Kadotani - Armata Pharmaceuticals Vice Operations
| ARMP Stock | USD 2.29 0.04 1.78% |
Executive
Bryan Kadotani is Vice Operations of Armata Pharmaceuticals
| Address | 5005 McConnell Avenue, Los Angeles, CA, United States, 90066 |
| Phone | 310 665 2928 |
| Web | https://www.armatapharma.com |
Armata Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2509) % which means that it has lost $0.2509 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (34.3935) %, meaning that it created substantial loss on money invested by shareholders. Armata Pharmaceuticals' management efficiency ratios could be used to measure how well Armata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/25/2024, Return On Equity is likely to grow to 2.26, while Return On Tangible Assets are likely to drop (0.86). As of 11/25/2024, Total Current Liabilities is likely to grow to about 17.3 M. Also, Liabilities And Stockholders Equity is likely to grow to about 103.3 MSimilar Executives
| Found 2 records | EXECUTIVE Age | ||
| John Roop | Anixa Biosciences | 74 | |
| Avraham Gabay | Biomx Inc | 38 | |
Management Performance
| Return On Equity | -34.39 | ||||
| Return On Asset | -0.25 |
Armata Pharmaceuticals Leadership Team
Elected by the shareholders, the Armata Pharmaceuticals' board of directors comprises two types of representatives: Armata Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Armata. The board's role is to monitor Armata Pharmaceuticals' management team and ensure that shareholders' interests are well served. Armata Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Armata Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Martin, Advisor | ||
| Richard Rychlik, VP Controller | ||
| Todd MBA, Advisor | ||
| Pierre Kyme, Senior Development | ||
| Peter Hubbard, Vice Operations | ||
| MS MD, Chief Officer | ||
| Duane BA, VP Operations | ||
| Wenyuan Shi, CoFounder Scientist | ||
| David House, Senior Officer | ||
| Deborah MD, CEO Director | ||
| Brian Varnum, CEO Director | ||
| Bryan Kadotani, Vice Operations | ||
| Erin Butler, Principal Admin |
Armata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Armata Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -34.39 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (11.31) % | ||||
| Current Valuation | 204.6 M | ||||
| Shares Outstanding | 36.18 M | ||||
| Shares Owned By Insiders | 70.24 % | ||||
| Shares Owned By Institutions | 3.82 % | ||||
| Number Of Shares Shorted | 4.54 K | ||||
| Price To Earning | (1.65) X | ||||
| Price To Book | 4.06 X |
Pair Trading with Armata Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.
The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.